A group meets for a presentation in a glass-walled conference room, while a woman talks on the phone in the background

News

Explore our progress developing efruxifermin as a novel treatment for metabolic dysfunction-associated steatohepatitis (MASH).

Akero Corporate Presentation Thumbnail

View our latest corporate presentation to learn more about Akero.

Download

12/09/2025

Novo Nordisk has completed its acquisition of Akero Therapeutics

11/07/2025

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

10/09/2025

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

08/14/2025

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

05/10/2025

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

05/09/2025

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

05/09/2025

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

02/28/2025

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

01/27/2025

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

01/13/2025

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD